Related references
Note: Only part of the references are listed.Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway
Yu Liang et al.
ONCOGENE (2020)
Acidosis-induced metabolic reprogramming in tumor cells enhances the anti-proliferative activity of the PDK inhibitor dichloroacetate
C. A. Schoonjans et al.
CANCER LETTERS (2020)
Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism
Jerome Ruhnau et al.
BMC CANCER (2020)
Dichloroacetic acid upregulates apoptosis of ovarian cancer cells by regulating mitochondrial function
Li Zhou et al.
ONCOTARGETS AND THERAPY (2019)
Dichloroacetate Affects Mitochondrial Function and Stemness-Associated Properties in Pancreatic Cancer Cell Lines
Tiziana Tataranni et al.
CELLS (2019)
Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma
Haiquan Lu et al.
JCI INSIGHT (2019)
Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer
Xiao Lu et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Dichloroacetic acid (DCA) synergizes with the SIRT2 inhibitor Sirtinol and AGK2 to enhance anti-tumor efficacy in non-small cell lung cancer
Wenjing Ma et al.
CANCER BIOLOGY & THERAPY (2018)
Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells
Zeiyad Alkarakooly et al.
PLOS ONE (2018)
Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC
Christopher T. Lucido et al.
CANCERS (2018)
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients
Evangelos D. Michelakis et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.
R. Tibes et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mitochondrial dysfunction-mediated apoptosis resistance associates with defective heat shock protein response in African-American men with prostate cancer
Ajay K. Chaudhary et al.
BRITISH JOURNAL OF CANCER (2016)
Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma
Mingxiao Lang et al.
CANCER LETTERS (2016)
Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer
Jong-Lyel Roh et al.
CANCER LETTERS (2016)
Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines
Zheng Yang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors
Quincy Siu-Chung Chu et al.
INVESTIGATIONAL NEW DRUGS (2015)
Haplotype Variations in Glutathione Transferase Zeta 1 Influence the Kinetics and Dynamics of Chronic Dichloroacetate in Children
A. L. Shroads et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment
Vitalba Ruggieri et al.
ONCOTARGET (2015)
Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells
Allison B. Haugrud et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells
Yong Won Choi et al.
CANCER LETTERS (2014)
Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism
Yi Xuan et al.
EXPERIMENTAL CELL RESEARCH (2014)
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
E. M. Dunbar et al.
INVESTIGATIONAL NEW DRUGS (2014)
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer
Edward B. Garon et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3
Chiara Agnoletto et al.
ONCOTARGET (2014)
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
Y-C Shen et al.
BRITISH JOURNAL OF CANCER (2013)
Long-term safety of dichloroacetate in congenital lactic acidosis
Monica Abdelmalak et al.
MOLECULAR GENETICS AND METABOLISM (2013)
Mitochondrial activation by inhibition of PDKII suppresses HIF1α signaling and angiogenesis in cancer
G. Sutendra et al.
ONCOGENE (2013)
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani et al.
NATURE BIOTECHNOLOGY (2012)
Reactive oxygen species downregulate glucose transport system in retinal endothelial cells
Rosa Fernandes et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
Improving posttransplantation survival of human ovarian tissue by treating the host and graft
Ronit Abir et al.
FERTILITY AND STERILITY (2011)
Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells
Jing Xie et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2011)
Dichloroacetate Induces Apoptosis of Epithelial Ovarian Cancer Cells Through a Mechanism Involving Modulation of Oxidative Stress
Ghassan M. Saed et al.
REPRODUCTIVE SCIENCES (2011)
HIF-1 prevents the overproduction of mitochondrial ROS after cytokine stimulation through induction of PDK-1
Keita Kirito et al.
CELL CYCLE (2009)
Dichloroacetate induces apoptosis in endometrial cancer cells
Jason Y. Y. Wong et al.
GYNECOLOGIC ONCOLOGY (2008)
PX-478, an inhibitor of hypoxia-inducible factor-1α, enhances radiosensitivity of prostate carcinoma cells
Sanjeewani T. Palayoor et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 alpha
Mei Y. Koh et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Preclinical versus clinical drug combination studies
Ting-Chao Chou
LEUKEMIA & LYMPHOMA (2008)
The Warburg effect and its cancer therapeutic implications
Zhao Chen et al.
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2007)
A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth
Sebastien Bonnet et al.
CANCER CELL (2007)
Multi-target therapeutics: when the whole is greater than the sum of the parts
Grant R. Zimmermann et al.
DRUG DISCOVERY TODAY (2007)
HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia
JW Kim et al.
CELL METABOLISM (2006)
Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses
L Zhao et al.
CLINICAL CANCER RESEARCH (2004)
Induction of HIF-1α in response to hypoxia is instantaneous
UR Jewell et al.
FASEB JOURNAL (2001)
Share Paper
